|
1
|
Zhao P, Dai M, Chen W and Li N: Cancer
trends in China. Jpn J Clin Oncol. 40:281–285. 2010. View Article : Google Scholar
|
|
2
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar
|
|
3
|
Cervantes A, Roda D, Tarazona N, et al:
Current questions for the treatment of advanced gastric cancer.
Cancer Treat Rev. 39:60–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive advanced gastric or gastro-oesophageal junction
cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Lancet. 376:687–697. 2010. View Article : Google Scholar
|
|
5
|
Ohtsu A, Shah MA, Van Cutsem E, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: a randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar
|
|
6
|
Lordick F, Kang YK, Chung HC, et al:
Arbeitsgemeinschaft Internistische Onkologie and EXPAND
Investigators: Capecitabine and cisplatin with or without cetuximab
for patients with previously untreated advanced gastric cancer
(EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol.
14:490–499. 2013. View Article : Google Scholar
|
|
7
|
Waddell T, Chau I, Cunningham D, et al:
Epirubicin, oxaliplatin, and capecitabine with or without
panitumumab for patients with previously untreated advanced
oesophagogastric cancer (REAL3): a randomised, open-label phase 3
trial. Lancet Oncol. 14:481–489. 2013. View Article : Google Scholar
|
|
8
|
Cunningham D, Starling N, Rao S, et al:
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom: Capecitabine and
oxaliplatin for advanced esophagogastric cancer. N Engl J Med.
358:36–46. 2008. View Article : Google Scholar
|
|
9
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bang YJ, Kim YW, Yang HK, et al: CLASSIC
trial investigators; Adjuvant capecitabine and oxaliplatin for
gastric cancer after D2 gastrectomy (CLASSIC): a phase 3
open-label, randomised controlled trial. Lancet. 379:315–321. 2012.
View Article : Google Scholar
|
|
11
|
Shi M, Lou B, Ji J, et al: Synergistic
antitumor effects of dasatinib and oxaliplatin in gastric cancer
cells. Cancer Chemother Pharmacol. 72:35–44. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weichert W, Röske A, Gekeler V, et al:
Association of patterns of class I histone deacetylase expression
with patient prognosis in gastric cancer: a retrospective analysis.
Lancet Oncol. 9:139–148. 2008. View Article : Google Scholar
|
|
13
|
Barneda-Zahonero B and Parra M: Histone
deacetylases and cancer. Mol Oncol. 6:579–589. 2012. View Article : Google Scholar
|
|
14
|
Mann BS, Johnson JR, Cohen MH, et al: FDA
approval summary: vorinostat for treatment of advanced primary
cutaneous T-cell lymphoma. Oncologist. 12:1247–1252. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carew JS, Giles FJ and Nawrocki ST:
Histone deacetylase inhibitors: mechanisms of cell death and
promise in combination cancer therapy. Cancer Lett. 269:7–17. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yoo C, Ryu MH, Na YS, et al: Phase I and
pharmacodynamic study of vorinostat combined with capecitabine and
cisplatin as first-line chemotherapy in advanced gastric cancer.
Invest New Drugs. 32:271–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Raymond E, Faivre S, Chaney S, et al:
Cellular and molecular pharmacology of oxaliplatin. Mol Cancer
Ther. 1:227–235. 2002.
|
|
18
|
Petruccelli LA, Dupéré-Richer D,
Pettersson F, et al: Vorinostat induces reactive oxygen species and
DNA damage in acute myeloid leukemia cells. PLoS One. 6:e209872011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang C, Richon V, Ni X, et al: Selective
induction of apoptosis by histone deacetylase inhibitor SAHA in
cutaneous T-cell lymphoma cells: relevance to mechanism of
therapeutic action. J Invest Dermatol. 125:1045–1052. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen CS, Weng SC, Tseng PH, et al: Histone
acetylation-independent effect of histone deacetylase inhibitors on
Akt through the reshuffling of protein phosphatase 1 complexes. J
Biol Chem. 280:38879–38887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Claerhout S, Lim JY, Choi W, et al: Gene
expression signature analysis identifies vorinostat as a candidate
therapy for gastric cancer. PLoS One. 6:e246622011. View Article : Google Scholar
|
|
23
|
Diyabalanage HV, Granda ML and Hooker JM:
Combination therapy: histone deacetylase inhibitors and
platinum-based chemotherapeutics for cancer. Cancer Lett. 329:1–8.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rikiishi H, Shinohara F, Sato T, et al:
Chemosensitization of oral squamous cell carcinoma cells to
cisplatin by histone deacetylase inhibitor, suberoylanilide
hydroxamic acid. Int J Oncol. 30:1181–1188. 2007.PubMed/NCBI
|
|
25
|
Woynarowski JM, Faivre S, Herzig MC, et
al: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol.
58:920–927. 2000.PubMed/NCBI
|
|
26
|
Faivre S, Chan D, Salinas R, et al: DNA
strand breaks and apoptosis induced by oxaliplatin in cancer cells.
Biochem Pharmacol. 66:225–237. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Conti C, Leo E, Eichler GS, et al:
Inhibition of histone deacetylase in cancer cells slows down
replication forks, activates dormant origins, and induces DNA
damage. Cancer Res. 70:4470–4480. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
New M, Olzscha H and La Thangue NB: HDAC
inhibitor-based therapies: can we interpret the code? Mol Oncol.
6:637–656. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Thompson RC, Vardinogiannis I and Gilmore
TD: The sensitivity of diffuse large B-cell lymphoma cell lines to
histone deacetylase inhibitor-induced apoptosis is modulated by
BCL-2 family protein activity. PLoS One. 8:e628222013. View Article : Google Scholar
|
|
30
|
Hirsch CL, Smith-Windsor EL and Bonham K:
Src family kinase members have a common response to histone
deacetylase inhibitors in human colon cancer cells. Int J Cancer.
118:547–554. 2006. View Article : Google Scholar
|
|
31
|
Jiang T and Qiu Y: Interaction between Src
and a C-terminal proline-rich motif of Akt is required for Akt
activation. J Biol Chem. 278:15789–15793. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Summy JM and Gallick GE: Treatment for
advanced tumors: SRC reclaims center stage. Clin Cancer Res.
12:1398–1401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hsieh AC, Truitt ML and Ruggero D:
Oncogenic AKTivation of translation as a therapeutic target. Br J
Cancer. 105:329–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu J, Fu XQ, Zhou W, et al: LY294002
potentiates the anti-cancer effect of oxaliplatin for gastric
cancer via death receptor pathway. World J Gastroenterol.
17:181–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
